Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM10 | O14672 | 20/20 | 0.74 |
| ▸ | MMP2 | P08253 | 16/20 | 0.74 |
| ▸ | ERBB2 | P04626 | 10/20 | 0.74 |
| ▸ | MMP9 | P14780 | 9/20 | 0.74 |
| ▸ | MMP3 | P08254 | 4/20 | 0.59 |
| ▸ | MMP1 | P03956 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1364953 | 1.00 | ADAM10 (0.74) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL1363663 | 1.00 | ADAM10 (0.74) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL1364940 | 0.91 | ADAM10 (0.68) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL1364044 | 0.91 | ADAM10 (0.68) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL1363704 | 0.85 | ADAM10 (1.00) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL1364677 | 0.85 | ADAM10 (1.00) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL1364984 | 0.82 | ADAM10 (0.92) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL1366658 | 0.82 | ADAM10 (0.92) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL1363898 | 0.81 | ADAM10 (1.00) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL1366383 | 0.81 | ADAM10 (1.00) | ADAM10MMP2ERBB2MMP9MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170035751-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | INCYTE CORPORATION | 2017-02-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035751-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | MMP9, MMP3, MMP12 | ADAM10 29/4885MMP2 23/4885ERBB2 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.